Literature DB >> 22264869

Osteopontin (OPN) improves risk stratification in pulmonary hypertension (PH).

Mark Rosenberg, F Joachim Meyer, Ekkehard Gruenig, Tibor Schuster, Matthias Lutz, Dirk Lossnitzer, Rita Wipplinger, Hugo A Katus, Norbert Frey.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22264869     DOI: 10.1016/j.ijcard.2011.12.108

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  9 in total

Review 1.  Biomarkers in pulmonary arterial hypertension.

Authors:  Julie L Rosenthal; Miriam S Jacob
Journal:  Curr Heart Fail Rep       Date:  2014-12

2.  Mechanism of IFN-γ in regulating OPN/Th17 pathway during vascular collagen remodeling of hypertension induced by ANG II.

Authors:  Lei Jiang; Pengcheng He; Yong Liu; Jiyan Chen; Xuebiao Wei; Ning Tan
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

3.  Persistently elevated osteopontin serum levels predict mortality in critically ill patients.

Authors:  Christoph Roderburg; Fabian Benz; David Vargas Cardenas; Matthias Lutz; Hans-Joerg Hippe; Tom Luedde; Christian Trautwein; Norbert Frey; Alexander Koch; Frank Tacke; Mark Luedde
Journal:  Crit Care       Date:  2015-06-26       Impact factor: 9.097

Review 4.  Role of Biomarkers in the Diagnosis, Risk Assessment, and Management of Pulmonary Hypertension.

Authors:  Vanessa Rameh; Antoine Kossaify
Journal:  Biomark Insights       Date:  2016-06-23

Review 5.  Novel Molecular Mechanisms of Pulmonary Hypertension: A Search for Biomarkers and Novel Drug Targets-From Bench to Bed Site.

Authors:  Damian Gajecki; Jakub Gawrys; Ewa Szahidewicz-Krupska; Adrian Doroszko
Journal:  Oxid Med Cell Longev       Date:  2020-05-22       Impact factor: 6.543

Review 6.  Comorbidity in idiopathic pulmonary fibrosis - what can biomarkers tell us?

Authors:  Tiago M Alfaro; Carlos Robalo Cordeiro
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

7.  Role of Osteopontin as a Potential Biomarker of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Other Connective Tissue Diseases (CTDs).

Authors:  Mattia Bellan; Cristina Piccinino; Stelvio Tonello; Rosalba Minisini; Ailia Giubertoni; Daniele Sola; Roberta Pedrazzoli; Ileana Gagliardi; Erika Zecca; Elisa Calzaducca; Federica Mazzoleni; Roberto Piffero; Giuseppe Patti; Mario Pirisi; Pier Paolo Sainaghi
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-21

Review 8.  An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers.

Authors:  Joana Santos-Gomes; Inês Gandra; Rui Adão; Frédéric Perros; Carmen Brás-Silva
Journal:  Front Cardiovasc Med       Date:  2022-07-14

Review 9.  Clinical and Molecular Implications of Osteopontin in Heart Failure.

Authors:  Argen Mamazhakypov; Meerim Sartmyrzaeva; Akpay Sh Sarybaev; Ralph Schermuly; Akylbek Sydykov
Journal:  Curr Issues Mol Biol       Date:  2022-08-11       Impact factor: 2.976

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.